✦ LIBER ✦

Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

✍ Scribed by Wang, Dian; Zhang, Qiang; Blanke, Charles D.; Demetri, George D.; Heinrich, Michael C.; Watson, James C.; Hoffman, John P.; Okuno, Scott; Kane, John M.; Mehren, Margaret; Eisenberg, Burton L.

Book ID: 115031723
Publisher: Springer
Year: 2012
Tongue: English
Weight: 153 KB
Volume: 19
Category: Article
ISSN: 1068-9265
DOI: 10.1245/s10434-012-2228-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of Neoadjuvant/adjuvant I

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

✍ Dian Wang; Qiang Zhang; Charles D. Blanke; George D. Demetri; Michael C. Heinric 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 507 KB

Phase II trial of neoadjuvant/adjuvant i

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

✍ Burton L. Eisenberg; Jonathan Harris; Charles D. Blanke; George D. Demetri; Mich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB